SB225002
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
Product Specifications
CAS Number
182498-32-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/SB225002.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(NC1=CC=C([N+]([O-])=O)C=C1O)NC2=CC=CC=C2Br
Molecular Formula
C13H10BrN3O4
Molecular Weight
352.14
Precautions
H302, H315, H319, H335
References & Citations
[1]White JR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem. 1998 Apr 24;273 (17) :10095-8.|[2]Wang B, et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006 Mar 15;66 (6) :3071-7.|[3]Herz J, et al. Role of Neutrophils in Exacerbation of Brain Injury After Focal Cerebral Ischemia in Hyperlipidemic Mice. Stroke. 2015 Oct;46 (10) :2916-25.|[4]Wang LY, et al. CXCL5 signaling is a shared pathway of neuroinflammation and blood-brain barrier injury contributing to white matter injury in the immature brain. J Neuroinflammation. 2016 Jan 6;13:6.|[5]Shi ZR, et al. Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. J Autoimmun. 2018 May;89:30-40.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA725091 100 µL
Human Clusterin Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
